Market Analysis: Global Pyelonephritis Treatment Market
Pyelonephritis Treatment Market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Emergence of drugs used to treat risk associated with Mediterranean fever and high demand of disease specific novel therapies are the key factors that fueling the market growth.
Market Definition: Global Pyelonephritis Treatment Market
Pyelonephritis is also known as kidney infection is characterized by infections of one or both side of kidney. It can lead to permanently damage to the kidney and can cause a life-threatening infection. People with kidney infection may experience fever, abdominal pain strong, persistent urge to urinate and nausea etc.
Get More Insights About Global Pyelonephritis Treatment Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pyelonephritis-treatment-market
Market Drivers
• Growing prevalence of kidney infections and injuries worldwide is drive the market growth
• Huge financial support to the researchers for developing novel intervention is boosting the market growth
• High demand of disease specific novel treatment can also act as a market driver
• Recent launch of product and emerging new market is propelling g the market growth
Market Restraints
• Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market
• Low healthcare budget in some developing countries is hamper the market growth
Know more about this report https://www.databridgemarketresearch.com/reports/global-pyelonephritis-treatment-market
Segmentation: Global Pyelonephritis Treatment Market
By Type
• Acute Pyelonephritis
• Chronic Pyelonephritis
By Treatment
• Medication
• Surgery
By Drugs
• Plazomicin
• Levofloxacin
• Meropenem and Vaborbactam
• Others
By Route of Administration
• Oral
• Injectable
By End Users
• Hospitals
• Homecare
• Specialty Clinics
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Others
By Geography
• North America
o U.S.
o Canada
o Mexico
• South America
o Brazil
o Rest of South America
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Russia
o Turkey
o Belgium
o Netherlands
o Switzerland
o Rest of Europe
• Asia-Pacific
o Japan
o China
o South Korea
o India
o Australia
o Singapore
o Thailand
o Malaysia
o Indonesia
o Philippines
o Rest of Asia Pacific
• Middle East & Africa
o South Africa
o Rest of Middle East & Africa
Key Developments in the Market:
• In July 2019, Cipla USA Inc, a subsidiary of Cipla Inc acquired worldwide rights excluding Greater China for prescription drug Zemdri (Plazomicin), an aminoglycoside antibacterial for the treatment of complicated Urinary Tract Infections (cUTI) including pyelonephritis from Achaogen Inc. The acquisition of Zemdri, expands the company’s infectious portfolio as well as represent major advances in the treatment of these patients through a targeted mode of action.
• In November 2018, MELINTA THERAPEUTICS, INC received approval from the European Commission (EC) for Vabomere (meropenem and vaborbactam) for the treatment of complicated intra-abdominal (cIAI) and urinary tract infections (cUTI) including pyelonephritis and hospital-acquired pneumonia including ventilator associated pneumonia. The approval of Vabomere has significantly changed the treatment landscape for underserved patient population.
Get Access Report @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-pyelonephritis-treatment-market
Competitive Analysis:
Global pyelonephritis treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global pyelonephritis treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Key Market Players:
Few of the major competitors currently working in the global pyelonephritis treatment market are MELINTA THERAPEUTICS, INC, Cipla Inc, Johnson & Johnson Services, Inc, Allecra Therapeutics, Entasis Therapeutics, Pfizer Inc, Allergan, Paratek Pharmaceuticals Inc, Spero Therapeutics, MerLion Pharmaceuticals GmbH, Merck & Co., Inc, VenatoRx Pharmaceuticals, Inc, Venus Remedies Limited, Nabriva Therapeutics plc, Shionogi Inc, Bayer AG, Takeda Pharmaceutical Company Limited and others.
Primary Respondents
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Request for Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-pyelonephritis-treatment-market
Browse Trending Related Reports @
• Rosacea Treatment Market
• Smith-Lemli-Opitz Syndrome Market
• Urothelial Cancer Drugs Market
• Vitiligo Treatment Market
• Dry Eye Syndrome Market
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]